# TB:HV an international prospective observational study


Tuberculosis among HIV-positive patients: an international prospective observational study

# Scientific Update

Results from the retrospective phase of the HIV/TB study will be presented during 13th European AIDS Conference/EACS in Belgrade, Serbia from October 12-15, 2011. The presentation "Mortality rate, TB recurrence and causes of death in HIV/TB coinfected patients: results from the HIV/TB collaborative study" will be held on **Friday, October 14th at 14:15-14:30** during the session, The Best of HIV Observational Cohort Research (in Hall 1).

# **Ethical Approvals**

More sites have obtained approval from their Ethics Committees as shown in Figure 1. Congratulations on this and we thank all the sites for their dedication and hard efforts to get study approvals in place. We realize the ethical approval process can be lengthy, so we will **extend the deadline for submission of Enrolment forms to 31 October 2011** (for all HIV patients diagnosed with TB during January – June 2011).



## Figure 1 Ethical Approval Status

# Enrolment status and deadline

199 enrolment forms have been submitted to the coordinating centre up to date. The majority have arrived from the Eastern European Countries as shown in Figure 2.

Many thanks to all investigators for their time used on completion of the forms!

## **Investigator Meeting**

There will be an TB:HIV Study Investigators meeting in conjunction with 13th EACS Conference in Belgrade, Serbia. Friday, October 14th at 16:00 -17:00, Hotel Hyatt Regence Belgrade, Milentija Popovica 5, room Beograd. Hotel is located in 5 min walking distance from the Conference Centre. Snack and beverages will be provided during the meeting. Please forward this information to all relevant persons involved in the study. We are looking very much forward to seeing everybody in Belgrade!

#### **Prospective Study Status**

15 European countries have agreed to participate (as listed below). We thank all investigators for their willingness to participate and contribute to the study!




Figure 2 Enrolment forms collected 2011

### **Mycobacterial Samples**

We have established a collaboration with Statens Serum Institut (SSI), a central laboratory in Copenhagen, Denmark, which will enable analyses of the mycobacterial samples (resistance testing and genotyping). All samples should be stored locally and shipped to CHIP once per year. Please ensure with your laboratory that they store all positive samples until shipment. You will be reimbursed 30 euro for each sample and all shipment costs will be covered by the project. CHIP will be providing you with step-by-step instructions for handling and shipping samples. If you have any questions in the meantime, please email <u>hivtb@cphiv.dk</u>.

TB: HIV Study Group: Participating Countries and cities **Central Northern Europe**: Denmark (Danish HIV Cohort): France (Aquitaine Cohort): Switzerland (Swiss HIV Cohort): United Kingdom; Manchester, London (4 clinics), Sheffield, Leicester **Southern Europe**: Greece; Athens: Italy; Bari, Brescia, Genova, Monza, Palermo, Rome, Sanremo, San Paolo Spain; Barcelona (6 clinics), Madrid, San Sebastián **Latin America:** Argentina; Buenos Aires **Eastern Europe**: Belarus; Gomel, Minsk, Svetlogorsk: Estonia; Ida-Viru county: Latvia; Riga: Lithuania; Vilnius: Poland; Bialystok, Warsaw, Wroclaw: Romania; Bucharest: Russia; Novgorod the Great, St. Petersburg: Ukraine; Kharkov

TB:HIV Study Coordinating Centre: Copenhagen HIV Programme, University of Copenhagen, Faculty of Health Sciences, The Panum Institute/Building 21.1, Blegdamsvej 3B, 2200 Copenhagen N, Denmark, Tel: +45 35 45 57 57, Fax: +45 35 45 57 58, e-mail: hivtb@cphiv.dk website: <u>http://www.chip.dk/</u>